Related Experiment Videos
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor
L Hanus1, A Breuer, S Tchilibon
1Department of Medicinal Chemistry, Medical Faculty, Hebrew University, Jerusalem 91120, Israel.
Summary
Researchers developed HU-308, a specific agonist for the CB(2) receptor, which lacks central nervous system (CNS) effects. This novel cannabinoid shows potential for treating inflammation, pain, and hypertension without psychotropic activity.
Area of Science:
- Pharmacology
- Neuroscience
- Immunology
Background:
- Two cannabinoid receptors, CB(1) and CB(2), have been identified with distinct tissue distributions.
- CB(1) receptors are primarily in the CNS, mediating tetrahydrocannabinol (THC)-like effects.
- CB(2) receptors are predominantly in peripheral organs, with evidence of their presence in peripheral nerve terminals.
Purpose of the Study:
- To synthesize and characterize a novel CB(2)-specific agonist, HU-308.
- To evaluate the pharmacological profile of HU-308, including its binding affinity and functional activity at CB(1) and CB(2) receptors.
- To assess the in vivo effects of HU-308 in animal models, focusing on potential therapeutic applications.
Main Methods:
- Synthesis of the CB(2)-specific agonist HU-308.
- Binding assays to determine affinity for CB(1) and CB(2) receptors.
- Functional assays measuring forskolin-stimulated cyclic AMP production in transfected cells.
- In vivo behavioral tests in mice, including a tetrad specific for CB(1) activity.
- Administration of HU-308 and antagonists (SR-144528, SR-141716A) to assess effects on blood pressure, defecation, inflammation, and pain.
Main Results:
- HU-308 demonstrated high specificity for CB(2) receptors (K(i) = 22.7 +/- 3.9 nM) with negligible binding to CB(1) receptors (K(i) > 10 microM).
- HU-308 inhibited cyclic AMP production in CB(2)-transfected cells but not significantly in CB(1)-transfected cells.
- In vivo, HU-308 did not produce THC-like CNS effects but reduced blood pressure, blocked defecation, and exhibited anti-inflammatory and peripheral analgesic activity.
- These peripheral effects were antagonized by SR-144528 (CB(2) antagonist) but not by SR-141716A (CB(1) antagonist).
Conclusions:
- HU-308 is a potent and selective CB(2) receptor agonist.
- The study validates the feasibility of developing novel, nonpsychotropic cannabinoids targeting CB(2) receptors.
- These findings suggest potential therapeutic applications for HU-308 and related compounds in managing hypertension, inflammation, and peripheral pain.